Synergistic activity of the combination has been demonstrated between SMAC mimetics and TRAIL in a number of tumour models and induces cell death in sensitive models;1 recently, a phase I clinical trial has been initiated to evaluate a combined regimen of a SMAC mimetic, birinapant, with an agonist monoclonal antibody against TRAIL-R2, conatumumab15 with anticipation that improved clinical response will be observed with this combination than monotherapy TRA treatment. This evidence concerns the gene TNFSF10 and neoplasm.